Brussels, 19/09/2013 (Agence Europe) - The European Commission has finally accepted the decision of the General Court of the EU and has granted CTRS marketing authorisation for the medicine known as Orphacol. The intended use of this orphan medicine is for treating two extremely rare and potentially fatal liver diseases. In a press release on 18 September, the French laboratory CTRS welcomed this decision but said, nevertheless, that it intended to take action against the Commission for...